Posted on September 24th, 2012 by
According to results presented at the 2012 Breast Cancer Symposium, the combination of Afinitor® (everolimus; also known as RAD001) and carboplatin may provide a benefit in metastatic, triple-negative breast cancer.
Triple-negative breast cancer is estrogen receptor-negative, progesterone receptor-negative, and HER2-negative. Because it generally does not respond to treatment with hormone therapy or HER2-targeted therapy, this type of breast cancer currently has fewer treatment options than other types of breast cancer.
Targeted therapies are drugs that interfere with specific biological pathways that contribute to cancer growth. The identification of effective targeted therapies for triple-negative breast cancer is an important research priority. In addition to developing new drugs specifically for this type of cancer, it’s possible that some existing drugs that have been approved for other purposes may also provide a benefit against triple-negative breast cancer.
Afinitor is a targeted therapy that works by inhibiting a protein known as mTOR. The mTOR protein plays an important role in regulating cancer cell division and blood vessel growth. Currently, Afinitor is used for the treatment of selected patients with kidney cancer, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma (SEGA), and hormone receptor-positive breast cancer.
To evaluate the combination of Afinitor and carboplatin (a chemotherapy drug) among women with triple-negative breast cancer, researchers are conducting a Phase II clinical trial among 25 women with metastatic, triple-negative breast cancer. Study participants are allowed to have received up to three prior chemotherapy regimens.
These results suggest that the combination of Afinitor and carboplatin may provide a benefit among women with metastatic, triple-negative breast cancer.
Singh JC, Volm M, Novik Y et al. Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study. Presented at the 2012 Breast Cancer Symposium. September 13-15, 2012.San Francisco,CA. Abstract 108.
Copyright © 2012 CancerConsultants. All Rights Reserved.
You must be logged-in to the site to post a comment.
Page loaded in 0.256 seconds